

FIRST CERTIFICATION IN ENDOCANNABINOID MEDICINE WITH CME FOR HEALTHCARE PROFESSIONALS NOW AVAILABLE

12-credit interactive learning program addresses missing link in medical education

Despite expansion of state medical cannabis programs, three FDA approved prescription cannabinoid medicines, and more cannabinoid medicines in clinical development, most healthcare professionals lack the training required to incorporate medical cannabis, Rx cannabinoid medicines, or even hemp-based products into medical practice. Most medical schools do not yet educate on the human endocannabinoid system (ECS) or recognize it as a therapeutic target, with ONLY 9% of medical schools offering educational curriculum about medical cannabis.*

Bridging the medical training gap, successful completion of the Havas ECS Endocannabinoid Medicine Certification program confers a total of twelve (12) *AMA PRA Category 1 Credits™* and a Certificate in Endocannabinoid Medicine from the American Journal of Endocannabinoid Medicine. Licensed Nurses and Pharmacists may apply to their boards for recognition of *AMA PRA Category 1 Credits™*. Available to physicians, nurses, and pharmacists, the Endocannabinoid Medicine Certification program includes four comprehensively referenced learning modules, each with detailed illustrations and scientific explanation. [View the syllabus here.](#)

“This professional certification in endocannabinoid medicine is very different from training offerings in the hemp-CBD, medical cannabis, and cannabinoid pharma market, in that it was developed with the independence and integrity required for ACCME-accredited education of physicians”, said Jahan Marcu, PhD, editor-in-chief of the American Journal of Endocannabinoid Medicine. “We are proud to be part of a program that’s concise, clear and practical so that healthcare professionals can learn, engage, and apply credible information into their practice” continued Dr. Marcu. “Without such clarity, most patients are likely to continue to experience high-priced intervals of trial and error, and largely with unmet treatment expectations.”

Following successful program completion, healthcare professionals will be able to describe the therapeutic potential of the ECS and conditions that may be treated with cannabinoids, understand the receptor targets, signaling pathways of endocannabinoids, phytocannabinoids, and approved cannabinoid prescription therapies, and apply practical tips on dosing and titration by condition, including potential adverse reactions and drug-drug interactions.

As foundational interactive education designed to address the real-world needs of healthcare professionals regarding the ECS and medical practice, experts conclude “this course sets the standard for quality education materials regarding the endocannabinoid system and cannabis,” described Dr. Perry Solomon, San Francisco, CA, and previously Chief Medical Officer of HelloMD. Larry Downs, Esq. and CEO of the Medical Society of New Jersey added, “Our members, across medical specialties, deserve the best endocannabinoid medicine training available. This accredited endocannabinoid medicine certification program helps support our physicians as they carefully integrate prescription cannabinoids, medical cannabis, and non-prescription cannabinoids into medical practice.”

More information and courses can be found at www.ajemuniversity.com

AMA PRA Category 1 Credits™ is a trademark of the American Medical Association.